帕利珠单抗及呼吸道合胞病毒的新兴疗法 - Suppr

Suppr

超能文献

Palivizumab and emerging therapies for respiratory syncytial virus.

作者信息

Hoopes John Michael, Makari Doris, Groothuis Jessie

出版信息

Expert Opin Biol Ther. 2012 May;12(5):547-8; author reply 549. doi: 10.1517/14712598.2012.665048. Epub 2012 Feb 21.

DOI:10.1517/14712598.2012.665048

PMID:22348302

Abstract

摘要

相似文献

Palivizumab and emerging therapies for respiratory syncytial virus.

Expert Opin Biol Ther. 2012 May;12(5):547-8; author reply 549. doi: 10.1517/14712598.2012.665048. Epub 2012 Feb 21.

A review of palivizumab and emerging therapies for respiratory syncytial virus.

Expert Opin Biol Ther. 2011 Nov;11(11):1455-67. doi: 10.1517/14712598.2011.608062. Epub 2011 Aug 11.

Respiratory syncytial virus: old challenges and new approaches.

Pediatr Ann. 2005 Jan;34(1):62-8. doi: 10.3928/0090-4481-20050101-14.

Early-life wheezing and respiratory syncytial virus prevention.

N Engl J Med. 2013 May 9;368(19):1839-41. doi: 10.1056/NEJMe1302063.

Defining the burden of respiratory syncytial virus infection.

J Pediatr (Rio J). 2013 Nov-Dec;89(6):517-9. doi: 10.1016/j.jped.2013.08.002. Epub 2013 Sep 19.

Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis.

Pediatr Crit Care Med. 2011 Sep;12(5):580-8. doi: 10.1097/PCC.0b013e3182070990.

Respiratory syncytial virus and recurrent wheeze.

N Engl J Med. 2013 Aug 22;369(8):782. doi: 10.1056/NEJMc1307429.

Respiratory syncytial virus and recurrent wheeze.

N Engl J Med. 2013 Aug 22;369(8):782-3. doi: 10.1056/NEJMc1307429.

Respiratory syncytial virus: different criteria for palivizumab use in different areas?

South Med J. 2007 Jul;100(7):661-2. doi: 10.1097/SMJ.0b013e318070ca99.

Respiratory syncytial virus prophylaxis reduces chronic respiratory morbidity in prematurely born infants.

Evid Based Med. 2014 Apr;19(2):65. doi: 10.1136/eb-2013-101437. Epub 2013 Oct 18.

引用本文的文献

Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease.

Antiviral Res. 2014 Apr;104:1-6. doi: 10.1016/j.antiviral.2014.01.008. Epub 2014 Jan 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Palivizumab and emerging therapies for respiratory syncytial virus.

Expert Opin Biol Ther. 2012 May;12(5):547-8; author reply 549. doi: 10.1517/14712598.2012.665048. Epub 2012 Feb 21.

A review of palivizumab and emerging therapies for respiratory syncytial virus.

Expert Opin Biol Ther. 2011 Nov;11(11):1455-67. doi: 10.1517/14712598.2011.608062. Epub 2011 Aug 11.

Respiratory syncytial virus: old challenges and new approaches.

Pediatr Ann. 2005 Jan;34(1):62-8. doi: 10.3928/0090-4481-20050101-14.

Early-life wheezing and respiratory syncytial virus prevention.

N Engl J Med. 2013 May 9;368(19):1839-41. doi: 10.1056/NEJMe1302063.

Defining the burden of respiratory syncytial virus infection.

J Pediatr (Rio J). 2013 Nov-Dec;89(6):517-9. doi: 10.1016/j.jped.2013.08.002. Epub 2013 Sep 19.

Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis.

Pediatr Crit Care Med. 2011 Sep;12(5):580-8. doi: 10.1097/PCC.0b013e3182070990.

Respiratory syncytial virus and recurrent wheeze.

N Engl J Med. 2013 Aug 22;369(8):782. doi: 10.1056/NEJMc1307429.

Respiratory syncytial virus and recurrent wheeze.

N Engl J Med. 2013 Aug 22;369(8):782-3. doi: 10.1056/NEJMc1307429.

Respiratory syncytial virus: different criteria for palivizumab use in different areas?

South Med J. 2007 Jul;100(7):661-2. doi: 10.1097/SMJ.0b013e318070ca99.

Respiratory syncytial virus prophylaxis reduces chronic respiratory morbidity in prematurely born infants.

Evid Based Med. 2014 Apr;19(2):65. doi: 10.1136/eb-2013-101437. Epub 2013 Oct 18.

引用本文的文献

Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease.

Antiviral Res. 2014 Apr;104:1-6. doi: 10.1016/j.antiviral.2014.01.008. Epub 2014 Jan 23.